Sentinel lymph node (SLN) biopsy for the treatment of ductal carcinoma in situ (DCIS) is not necessary and generally should be limited to those patients with a core needle biopsy diagnosis of DCIS who are undergoing mastectomy. Used in this way, SLN biopsy will spare the majority of patients with occult invasive tumor the need for axillary lymph node dissection.
No takes yet. Share an insight, caveat, or question.
McMasters et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: